The Canadian Agency for Drugs and Technologies in Health (CADTH) issued a Common Drug Review (CDR) Update on August 1, which includes the following highlights:
- commencing September 1, 2017, CADTH will no longer seek individual permissions from patient groups and will be sharing all patient input submissions online (subject to patient groups requesting that personal identifying information be redacted in their initial submissions and summary of patient input);
- CADTH invited stakeholders to provide comments and feedback on its proposed revisions to the biosimilar review process;
- CADTH initiated stakeholder consultation on its proposed revisions to CDR and pan-Canadian Oncology Drug Review resubmission eligibility criteria; and
- CADTH extended its deadline for stakeholder comments and feedback on the consultation for Revising Common Drug Review Recommendations in the CADTH Therapeutic Review Process to September 15, 2017 at 5 pm EDT.